İmuneks Farma OsteoNext Plus 90 Tablets - Bone Health Dietary Supplement for Adults, Lactose, Gluten, and Sugar-Free

İmuneks Farma OsteoNext Plus 90 Tablets - Bone Health Dietary Supplement for Adults, Lactose, Gluten, and Sugar-Free, categorized under Joint, bone & connective tissue health in the Supplements vertical. It is scored on the Vyvata Scoring Framework — an independent 6-dimension rubric applied uniformly to every product Vyvata lists.

57/100 overall — Standard tier (50–69 band). Per-dimension breakdown: Evidence 62, Safety 62, Formulation 58, Manufacturing 55, Transparency 55, Sustainability 50. Scored as of 2026-08-24.

İmuneks Farma is a Turkish pharmaceutical-adjacent supplement brand, and OsteoNext Plus is positioned as a bone-health blend (typically Ca + Mg + D3 + K2 or similar). The 'Farma' pharmacy-channel positioning may translate to slightly better formulation than pure consumer brands, and the lactose/gluten/sugar-free callouts address real allergen concerns. Without full ingredient/dose disclosure on the title it's hard to verify K2 MK-7 inclusion or the calcium salt used, and third-party testing isn't documented at the reseller level. Would move to Standard-high 62+ with calcium citrate specified, K2 MK-7 included at 90-180 mcg (Knapen 2013), and per-active mg disclosure.

Strongest: Evidence at 62/100 (quality of published RCT support for the active ingredients at the label dose) and Safety at 62/100 (adverse-event profile, interaction risk, and dose ceiling). Weakest: Transparency at 55/100 (dose disclosure vs proprietary blends, and honesty of marketing claims) and Sustainability at 50/100 (sourcing practices, packaging, and corporate practice). All six dimensions feed the overall Vyvata score; a weakness on any one dimension pulls the overall down proportionally.

No third-party certifications (NSF, USP, ConsumerLab, or equivalent) were on record at the time of scoring. This affects the Manufacturing dimension score. The manufacturer may test internally or have obtained certification more recently — check the current product label for the most up-to-date information.

Would move to Standard-high 62+ with calcium citrate specified, K2 MK-7 included at 90-180 mcg (Knapen 2013), and per-active mg disclosure.

The top-ranked joint, bone & connective tissue health product in the Vyvata catalog is currently Albion Magnesium & Calcium with Vitamins D3 & K2 at 76/100. See the full ranked list of 199 scored products in this subcategory at https://vyvata.com/pages/best-joint-bone-and-connective-tissue-health-supplements-ranked.

The Vyvata Scoring Framework rates every listed product 0–100 across six dimensions: Evidence, Formulation, Manufacturing, Safety, Transparency, and Sustainability. Tier bands: Elite 85–100 (top-tier evidence + formulation + manufacturing), Verified 70–84 (strong on most dimensions), Standard 50–69 (solid but with weaknesses called out), Rejected 0–49 (specific failures documented). Rejected products remain listed with reasons. Full methodology at https://vyvata.com/pages/methodology.

The Vyvata score measures product integrity against a published rubric, not customer sentiment. For customer reviews and community discussion, search external platforms directly: Amazon (https://www.amazon.com/s?k=%C4%B0muneks%20Farma%20OsteoNext%20Plus%2090%20Tablets%20-%20Bone%20Health%20Dietary%20Supplement%20for%20Adults%2C%20Lactose%2C%20Gluten%2C%20and%20Sugar-Free),Google(https://www.google.com/search?q=%C4%B0muneks%20Farma%20OsteoNext%20Plus%2090%20Tablets%20-%20Bone%20Health%20Dietary%20Supplement%20for%20Adults%2C%20Lactose%2C%20Gluten%2C%20and%20Sugar-Free+reviews),Reddit(https://www.reddit.com/search/?q=%C4%B0muneks%20Farma%20OsteoNext%20Plus%2090%20Tablets%20-%20Bone%20Health%20Dietary%20Supplement%20for%20Adults%2C%20Lactose%2C%20Gluten%2C%20and%20Sugar-Free%20review),andTrustpilot(https://www.trustpilot.com/search?query=%C4%B0muneks%20Farma%20OsteoNext%20Plus%2090%20Tablets%20-%20Bone%20Health%20Dietary%20Supplement%20for%20Adults%2C%20Lactose%2C%20Gluten%2C%20and%20Sugar-Free).Vyvatadoesnotaggregate,republish,orlicensethosethird-partyreviews.